These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35723820)

  • 1. An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : Immunotherapy with rituximab, ocrelizumab, and ofatumumab.
    Ovchinnikov A; Findling O
    Wien Med Wochenschr; 2022 Nov; 172(15-16):359-364. PubMed ID: 35723820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocrelizumab and Other CD20
    Gelfand JM; Cree BAC; Hauser SL
    Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
    Frisch ES; Pretzsch R; Weber MS
    Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell-directed therapies in multiple sclerosis.
    Gasperi C; Stüve O; Hemmer B
    Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocrelizumab for the treatment of multiple sclerosis.
    Bigaut K; De Seze J; Collongues N
    Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell depletion in the treatment of multiple sclerosis.
    Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
    Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
    Margoni M; Preziosa P; Filippi M; Rocca MA
    J Neurol; 2022 Mar; 269(3):1316-1334. PubMed ID: 34382120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapies for multiple sclerosis targeting B cells.
    Milo R
    Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for the treatment of multiple sclerosis: a review.
    Chisari CG; Sgarlata E; Arena S; Toscano S; Luca M; Patti F
    J Neurol; 2022 Jan; 269(1):159-183. PubMed ID: 33416999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair.
    Havla J; Hohlfeld R
    Neurotherapeutics; 2022 Apr; 19(3):774-784. PubMed ID: 35289375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
    de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
    Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.
    Zhong M; van der Walt A; Campagna MP; Stankovich J; Butzkueven H; Jokubaitis V
    Neurotherapeutics; 2020 Oct; 17(4):1768-1784. PubMed ID: 33058021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
    Pukoli D; Vécsei L
    Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
    Kaegi C; Wuest B; Crowley C; Boyman O
    Front Immunol; 2021; 12():788830. PubMed ID: 35185862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis.
    Cotchett KR; Dittel BN; Obeidat AZ
    Mult Scler Relat Disord; 2021 Apr; 49():102787. PubMed ID: 33516134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies.
    Melzer N; Meuth SG
    Clin Exp Immunol; 2014 Mar; 175(3):359-72. PubMed ID: 24032475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
    Sellebjerg F; Blinkenberg M; Sorensen PS
    CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
    Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
    Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CD20 in multiple sclerosis - review of current treatment strategies.
    Chmielewska N; Szyndler J
    Neurol Neurochir Pol; 2023; 57(3):235-242. PubMed ID: 36999373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.